DaTSCAN™ Ioflupane (123I) Injection

DRUG2 trials

Sponsors

GE Healthcare

Conditions

Essential TremorHealthy Subjects (HS)Multiple System Atrophy (MSA)Parkinson Disease(PD)Parkinsonian SyndromeProgressive Supranuclear Palsy (PSP)

Phase 1

A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

CompletedNCT04564092

GE HealthcareHealthy Subjects (HS)

Start: 2021-05-13End: 2021-09-04Updated: 2023-08-02

Phase 3

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

CompletedNCT04193527

GE HealthcareEssential Tremor, Multiple System Atrophy (MSA), Parkinson Disease(PD) +2

Start: 2020-06-28End: 2021-12-20Updated: 2023-10-16

Related Papers

Safety, biodistribution and radiation dosimetry of [123I]ioflupane in healthy Chinese volunteers

EJNMMI Research2023-04-071 citations